Authors
Yulin Haw, Wen-Yu Hsiao, Haider A Mejbel
Published in
International journal of surgical pathology. Pages 10668969261495964. Nov 17, 2026. Epub Nov 17, 2026.
Abstract
RSPO3 fusion activates the Wnt/β-catenin pathway at the level of upstream Wnt ligands, rather than directly through APC/CTNNB1 mutations. Beyond colorectal carcinoma, RSPO3 fusions remain underexplored. Herein, we report the first case series of PTPRK::RSPO3 fusion-positive small intestinal adenocarcinoma. Among 115 genomically profiled small intestinal adenocarcinomas, 5 (4%) patients were identified, including 4 (80%) women and 1 (20%) man, aged 51 to 69 years (mean = 59), of African American (4/5; 80%) and White (1/5; 20%) ethnicity. Tumors arose from the jejunum (4/5; 80%) and duodenum (1/5; 20%), with a mean size of 4.7 cm. All tumors were adenocarcinoma, not otherwise specified, with mucinous features in 2/5 (40%), presenting at pT4 with lymphovascular and perineural invasion, and were mismatch repair-proficient/microsatellite stable, ERBB2 (HER2)-negative, and PD-L1 (CD274)-negative, with low tumor mutation burden and loss of heterozygosity. All fusion transcripts resulted from an in-frame PTPRK exon 1::RSPO3 exon 2 fusion. The molecular landscape demonstrated frequent mutations in TP53 (5/5 [100%]) and the MAPK pathway genes (KRAS, NRAS, BRAF; 4/5 [80%]), while being APC/CTNNB1/RNF43-wild-type. Despite multimodal therapy, all patients developed metastasis (peritoneum 5/5 [100%]; liver 4/5 [80%]), with a mean overall survival of 28.5 months. PTPRK::RSPO3 fusion defines a subset of small intestinal adenocarcinomas that shares a core molecular profile with its colorectal counterpart, exhibits aggressive behavior, and is a candidate for emerging Wnt-targeted therapies. Including RNA-based testing in the molecular profiling of small intestinal adenocarcinoma can identify rare yet targetable fusion genes that may inform patient selection for clinical trials.
PMID:
43042555
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0